Keyword: taxes

cable and satellite TV California Canada cannabis cap-and-trade capital capital allocation capital budgeting capital flows capital formation capital income capital markets capital outflows capital regulation capital requirements capital stock capitalism CAPM carbon emissions carbon leakage carbon prices carbon tax carbon taxes careers CARES Act cash central bank independence central banks charitable deductions charity charter schools chief executives childrearing children China Christmas climate change climate policies climate policy climate targets clusters college admissions college athletes college tuition commercial banks commercial property commodity markets communism competition competition policy competitiveness concentration congestion congestion charges congestion pricing Congress Congressional Budget Office Connecticut constitutional amendment consumer price index consumer prices consumer protection consumer welfare consumption consumption insurance contraception conventions coronabonds Coronavirus corporate boards corporate executives corporate investment corporate performance corporate reporting corporate reproting corporate social responsibility corporate tax corporate taxes cost disease cost of capital cost of living cost-benefit analysis costs of living Council of Economic Advisors COVID-19 credibility revolution credit credit cards credit risk creditors crime crypto assets cryptocurrencies cryptocurrency Cuba culture currencies currency currency manipulation currency reserves
US

Medicare Funding

This US survey examines (a) If it is implemented, the proposed increase in the tax rate on earned and business income above $400,000 in the Biden budget, along with other proposed changes to Medicare, would extend the solvency of the Medicare program for the next 25 years; (b) If it is implemented, the proposed reform of Medicare drug negotiations in the Biden budget is likely to lead to a substantial reduction in drug prices for beneficiaries; (c) If it is implemented, the proposed reform of Medicare drug negotiations in the Biden budget is likely to lead to a substantial reduction in the development of beneficial new drugs